Targeted cancer therapy: promise and reality (Q36786085)

16 August 2017

1 reference

title

Targeted cancer therapy: promise and reality (English)

1 reference

16 August 2017

Shoshana Klein

1

1 reference

PubMed ID

17419951

16 August 2017

Alexander Levitzki

series ordinal

2

1 reference

16 August 2017

1 January 2007

1 reference

Advances in Cancer Research

16 August 2017

1 reference

16 August 2017

97

1 reference

16 August 2017

295-319

1 reference

Prospective identification of tumorigenic breast cancer cells

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Genetically engineered models have advantages over xenografts for preclinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

EGF-ERBB signalling: towards the systems level

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Discontinuation of imatinib therapy after achieving a molecular response

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Chronic myeloproliferative disorders: a tyrosine kinase tale.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

The organotypic culture of HPV-transformed keratinocytes: an effective in vitro model for the development of new immunotherapeutic approaches for mucosal (pre)neoplastic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Targeting RAS signalling pathways in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Establishment of the human papillomavirus type 16 (HPV-16) life cycle in an immortalized human foreskin keratinocyte cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

131I-tositumomab therapy as initial treatment for follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Orthotopic models are necessary to predict therapy of transplantable tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Identification of bronchioalveolar stem cells in normal lung and lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Cancer. p53, guardian of the genome

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Topotecan combination chemotherapy in two new rodent models of retinoblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Radio-immunotherapy in low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Tyrphostins and other tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Targeting the PI3K-Akt pathway in human cancer: rationale and promise

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Immunotoxins containing Pseudomonas exotoxin A: a short history

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

p107 is a suppressor of retinoblastoma development in pRb-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Reactivation of mutant p53: a new strategy for cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Inhibition of insulin-dependent lipogenesis and anti-lipolysis by protein tyrosine kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Chronic myelogenous leukemia: mechanisms underlying disease progression.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Gene therapy for glioblastoma: future perspective for delivery systems and molecular targets

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Identification of human brain tumour initiating cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Mouse models of gastrointestinal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Gefitinib in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Cell cycle and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Cancer genes and the pathways they control

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

On the Origin of Cancer Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Concepts of human leukemic development.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997013-4

7 January 2021

10.1016/S0065-230X(06)97013-4

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17419951